Insight Molecular Diagnostics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 58

Employees

  • Stock Symbol
  • IMDX

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $2.14
  • (As of Friday Closing)

Insight Molecular Diagnostics General Information

Description

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Contact Information

Website
www.imdxinc.com
Formerly Known As
OncoCyte
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2 International Plaza Drive
  • Suite 510
  • Nashville, TN 37217
  • United States
+1 (615)
Primary Industry
Diagnostic Equipment
Other Industries
Discovery Tools (Healthcare)
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 2 International Plaza Drive
  • Suite 510
  • Nashville, TN 37217
  • United States
+1 (615)

Insight Molecular Diagnostics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Insight Molecular Diagnostics Stock Performance

As of 13-Nov-2026, Insight Molecular Diagnostics’s stock price is $2.14. Its current market cap is $70M with 32.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.14 $2.31 $2.07 - $7.92 $70M 32.7M 221K -$1.50

Insight Molecular Diagnostics Financials Summary

As of 30-Jun-2026, Insight Molecular Diagnostics has a trailing 12-month revenue of $1.67M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 165,380 199,418 40,696 14,425
Revenue 1,670 4,055 1,881 1,503
EBITDA (46,818) (47,906) (58,991) (23,123)
Net Income (49,359) (50,222) (60,663) (27,781)
Total Assets 29,443 25,756 35,081 74,892
Total Debt 2,625 3,497 3,664 2,869
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Insight Molecular Diagnostics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Insight Molecular Diagnostics‘s full profile, request access.

Request a free trial

Insight Molecular Diagnostics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access
Diagnostic Equipment
Nashville, TN
58 As of 2025

Tucson, AZ
 

Fremont, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Insight Molecular Diagnostics Competitors (22)

One of Insight Molecular Diagnostics’s 22 competitors is HTG Molecular Diagnostics, a Formerly VC-backed company based in Tucson, AZ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
HTG Molecular Diagnostics Formerly VC-backed Tucson, AZ
BioGenex Laboratories Corporation Fremont, CA
RareCyte Venture Capital-Backed Seattle, WA
Oncimmune Formerly VC-backed Cambridge, MA
Precipio Formerly VC-backed New Haven, CT
You’re viewing 5 of 22 competitors. Get the full list »

Insight Molecular Diagnostics Patents

Insight Molecular Diagnostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023216680-A1 Classifying tumors and predicting responsiveness Pending 02-Feb-2022
EP-4473313-A2 Classifying tumors and predicting responsiveness Pending 02-Feb-2022
EP-4473313-A4 Classifying tumors and predicting responsiveness Pending 02-Feb-2022
US-20250140406-A1 Classifying tumors and predicting responsiveness Pending 02-Feb-2022
WO-2023150194-A2 Classifying tumors and predicting responsiveness Inactive 02-Feb-2022 G16H50/20
To view Insight Molecular Diagnostics’s complete patent history, request access »

Insight Molecular Diagnostics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Insight Molecular Diagnostics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Insight Molecular Diagnostics‘s full profile, request access.

Request a free trial

Insight Molecular Diagnostics Investments & Acquisitions (5)

Insight Molecular Diagnostics’s most recent deal was a Merger/Acquisition with Chronix Biomedical for . The deal was made on 19-Apr-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Chronix Biomedical 19-Apr-2021 Merger/Acquisition Laboratory Services (Healthcare)
Riskreveal 25-Feb-2021 Merger/Acquisition Diagnostic Equipment
Insight Genetics 31-Jan-2020 Merger/Acquisition Other Devices and Supplies
Riskreveal 05-Sep-2019 Secondary Transaction - Private Diagnostic Equipment
Cell Targeting 28-Jan-2011 Merger/Acquisition Biotechnology
To view Insight Molecular Diagnostics’s complete investments and acquisitions history, request access »

Insight Molecular Diagnostics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.97 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Insight Molecular Diagnostics’s complete esg history, request access »

Insight Molecular Diagnostics FAQs

  • When was Insight Molecular Diagnostics founded?

    Insight Molecular Diagnostics was founded in 2009.

  • Where is Insight Molecular Diagnostics headquartered?

    Insight Molecular Diagnostics is headquartered in Nashville, TN.

  • What is the size of Insight Molecular Diagnostics?

    Insight Molecular Diagnostics has 58 total employees.

  • What industry is Insight Molecular Diagnostics in?

    Insight Molecular Diagnostics’s primary industry is Diagnostic Equipment.

  • Is Insight Molecular Diagnostics a private or public company?

    Insight Molecular Diagnostics is a Public company.

  • What is Insight Molecular Diagnostics’s stock symbol?

    The ticker symbol for Insight Molecular Diagnostics is IMDX.

  • What is the current stock price of Insight Molecular Diagnostics?

    As of 13-Nov-2026 the stock price of Insight Molecular Diagnostics is $2.14.

  • What is the current market cap of Insight Molecular Diagnostics?

    The current market capitalization of Insight Molecular Diagnostics is $70M.

  • What is Insight Molecular Diagnostics’s current revenue?

    The trailing twelve month revenue for Insight Molecular Diagnostics is $1.67M.

  • Who are Insight Molecular Diagnostics’s competitors?

    HTG Molecular Diagnostics, BioGenex Laboratories, RareCyte, Oncimmune, and Precipio are some of the 22 competitors of Insight Molecular Diagnostics.

  • What is Insight Molecular Diagnostics’s annual earnings per share (EPS)?

    Insight Molecular Diagnostics’s EPS for 12 months was -$1.50.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process